semaglutide and inflammation – the Surprising New Anti-Fibrosis Drug Ozempic (semaglutide), a medication FDA-approved

Huppke B et al

Clinically Proven Support for GLP-1 Users In a 2025 double-blind, placebo-controlled study over 6 weeks in New Jersey, SymptoGuard showed significant improvements for GLP-1 users compared to placebo

Having said that, I would say a good deal of primary care clinicians are not aware enough about these medications

This holistic view of your health allows for more tailored advice and adjustments from your care team Broad Compatibility: The flexibility to connect with a variety of smart devices and fitness apps ensures that you can maintain your preferred fitness routines and technologies while using our program